Hipra SARS-CoV-2 RBD recombinant protein vaccine (candidate)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Hipra SARS-CoV-2 RBD recombinant protein vaccine (candidate), covering 2026-03-11 to 2026-03-11. Get the full timeline:
Most recent: Clinical Trial Update: Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration. [Phase 2]